Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma

Adrian M. Dubuc, Marc Remke, Andrey Korshunov, Paul A. Northcott, Shing H. Zhan, Maria Mendez-Lago, Marcel Kool, David T W Jones, Alexander Unterberger, A. Sorana Morrissy, David Shih, John Peacock, Vijay Ramaswamy, Adi Rolider, Xin Wang, Hendrik Witt, Thomas Hielscher, Cynthia Hawkins, Rajeev Vibhakar, Sidney Croul & 7 others James T. Rutka, William A. Weiss, Steven J M Jones, Charles G Eberhart, Marco A. Marra, Stefan M. Pfister, Michael D. Taylor

Research output: Contribution to journalArticle

Abstract

Recent sequencing efforts have described the mutational landscape of the pediatric brain tumor medulloblastoma. Although MLL2 is among the most frequent somatic single nucleotide variants (SNV), the clinical and biological significance of these mutations remains uncharacterized. Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs. Group 3 and 4 MBs demonstrate somatic copy number aberrations, and transcriptional profiles that converge on modifiers of H3K27-methylation (EZH2, KDM6A, KDM6B), leading to silencing of PRC2-target genes. As PRC2-mediated aberrant methylation of H3K27 has recently been targeted for therapy in other diseases, it represents an actionable target for a substantial percentage of medulloblastoma patients with aggressive forms of the disease.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalActa Neuropathologica
Volume125
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Medulloblastoma
Histones
Methylation
Lysine
Mutation
Histone Code
Brain Neoplasms
Chromatin
Nucleotides
Pediatrics
Staining and Labeling
Population
Genes
Neoplasms

Keywords

  • Histone lysine methylation
  • KDM6A
  • Medulloblastoma
  • MLL2
  • PRC2

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Dubuc, A. M., Remke, M., Korshunov, A., Northcott, P. A., Zhan, S. H., Mendez-Lago, M., ... Taylor, M. D. (2013). Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathologica, 125(3), 373-384. https://doi.org/10.1007/s00401-012-1070-9

Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. / Dubuc, Adrian M.; Remke, Marc; Korshunov, Andrey; Northcott, Paul A.; Zhan, Shing H.; Mendez-Lago, Maria; Kool, Marcel; Jones, David T W; Unterberger, Alexander; Morrissy, A. Sorana; Shih, David; Peacock, John; Ramaswamy, Vijay; Rolider, Adi; Wang, Xin; Witt, Hendrik; Hielscher, Thomas; Hawkins, Cynthia; Vibhakar, Rajeev; Croul, Sidney; Rutka, James T.; Weiss, William A.; Jones, Steven J M; Eberhart, Charles G; Marra, Marco A.; Pfister, Stefan M.; Taylor, Michael D.

In: Acta Neuropathologica, Vol. 125, No. 3, 03.2013, p. 373-384.

Research output: Contribution to journalArticle

Dubuc, AM, Remke, M, Korshunov, A, Northcott, PA, Zhan, SH, Mendez-Lago, M, Kool, M, Jones, DTW, Unterberger, A, Morrissy, AS, Shih, D, Peacock, J, Ramaswamy, V, Rolider, A, Wang, X, Witt, H, Hielscher, T, Hawkins, C, Vibhakar, R, Croul, S, Rutka, JT, Weiss, WA, Jones, SJM, Eberhart, CG, Marra, MA, Pfister, SM & Taylor, MD 2013, 'Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma', Acta Neuropathologica, vol. 125, no. 3, pp. 373-384. https://doi.org/10.1007/s00401-012-1070-9
Dubuc, Adrian M. ; Remke, Marc ; Korshunov, Andrey ; Northcott, Paul A. ; Zhan, Shing H. ; Mendez-Lago, Maria ; Kool, Marcel ; Jones, David T W ; Unterberger, Alexander ; Morrissy, A. Sorana ; Shih, David ; Peacock, John ; Ramaswamy, Vijay ; Rolider, Adi ; Wang, Xin ; Witt, Hendrik ; Hielscher, Thomas ; Hawkins, Cynthia ; Vibhakar, Rajeev ; Croul, Sidney ; Rutka, James T. ; Weiss, William A. ; Jones, Steven J M ; Eberhart, Charles G ; Marra, Marco A. ; Pfister, Stefan M. ; Taylor, Michael D. / Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. In: Acta Neuropathologica. 2013 ; Vol. 125, No. 3. pp. 373-384.
@article{2132603a155a4e05bb5c6f10ad8dde3b,
title = "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma",
abstract = "Recent sequencing efforts have described the mutational landscape of the pediatric brain tumor medulloblastoma. Although MLL2 is among the most frequent somatic single nucleotide variants (SNV), the clinical and biological significance of these mutations remains uncharacterized. Through targeted re-sequencing, we identified mutations of MLL2 in 8 {\%} (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 {\%} (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 {\%} (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs. Group 3 and 4 MBs demonstrate somatic copy number aberrations, and transcriptional profiles that converge on modifiers of H3K27-methylation (EZH2, KDM6A, KDM6B), leading to silencing of PRC2-target genes. As PRC2-mediated aberrant methylation of H3K27 has recently been targeted for therapy in other diseases, it represents an actionable target for a substantial percentage of medulloblastoma patients with aggressive forms of the disease.",
keywords = "Histone lysine methylation, KDM6A, Medulloblastoma, MLL2, PRC2",
author = "Dubuc, {Adrian M.} and Marc Remke and Andrey Korshunov and Northcott, {Paul A.} and Zhan, {Shing H.} and Maria Mendez-Lago and Marcel Kool and Jones, {David T W} and Alexander Unterberger and Morrissy, {A. Sorana} and David Shih and John Peacock and Vijay Ramaswamy and Adi Rolider and Xin Wang and Hendrik Witt and Thomas Hielscher and Cynthia Hawkins and Rajeev Vibhakar and Sidney Croul and Rutka, {James T.} and Weiss, {William A.} and Jones, {Steven J M} and Eberhart, {Charles G} and Marra, {Marco A.} and Pfister, {Stefan M.} and Taylor, {Michael D.}",
year = "2013",
month = "3",
doi = "10.1007/s00401-012-1070-9",
language = "English (US)",
volume = "125",
pages = "373--384",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma

AU - Dubuc, Adrian M.

AU - Remke, Marc

AU - Korshunov, Andrey

AU - Northcott, Paul A.

AU - Zhan, Shing H.

AU - Mendez-Lago, Maria

AU - Kool, Marcel

AU - Jones, David T W

AU - Unterberger, Alexander

AU - Morrissy, A. Sorana

AU - Shih, David

AU - Peacock, John

AU - Ramaswamy, Vijay

AU - Rolider, Adi

AU - Wang, Xin

AU - Witt, Hendrik

AU - Hielscher, Thomas

AU - Hawkins, Cynthia

AU - Vibhakar, Rajeev

AU - Croul, Sidney

AU - Rutka, James T.

AU - Weiss, William A.

AU - Jones, Steven J M

AU - Eberhart, Charles G

AU - Marra, Marco A.

AU - Pfister, Stefan M.

AU - Taylor, Michael D.

PY - 2013/3

Y1 - 2013/3

N2 - Recent sequencing efforts have described the mutational landscape of the pediatric brain tumor medulloblastoma. Although MLL2 is among the most frequent somatic single nucleotide variants (SNV), the clinical and biological significance of these mutations remains uncharacterized. Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs. Group 3 and 4 MBs demonstrate somatic copy number aberrations, and transcriptional profiles that converge on modifiers of H3K27-methylation (EZH2, KDM6A, KDM6B), leading to silencing of PRC2-target genes. As PRC2-mediated aberrant methylation of H3K27 has recently been targeted for therapy in other diseases, it represents an actionable target for a substantial percentage of medulloblastoma patients with aggressive forms of the disease.

AB - Recent sequencing efforts have described the mutational landscape of the pediatric brain tumor medulloblastoma. Although MLL2 is among the most frequent somatic single nucleotide variants (SNV), the clinical and biological significance of these mutations remains uncharacterized. Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs. Group 3 and 4 MBs demonstrate somatic copy number aberrations, and transcriptional profiles that converge on modifiers of H3K27-methylation (EZH2, KDM6A, KDM6B), leading to silencing of PRC2-target genes. As PRC2-mediated aberrant methylation of H3K27 has recently been targeted for therapy in other diseases, it represents an actionable target for a substantial percentage of medulloblastoma patients with aggressive forms of the disease.

KW - Histone lysine methylation

KW - KDM6A

KW - Medulloblastoma

KW - MLL2

KW - PRC2

UR - http://www.scopus.com/inward/record.url?scp=84878857067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878857067&partnerID=8YFLogxK

U2 - 10.1007/s00401-012-1070-9

DO - 10.1007/s00401-012-1070-9

M3 - Article

VL - 125

SP - 373

EP - 384

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 3

ER -